Ticagrelor and PLATO study

Czech version

Authors: J. Špinar ¹; J. Vítovec ²
Authors‘ workplace: Interní kardiologická klinika FN Brno-Bohunice a LF MU Brno ¹; I. interní kardioangiologická klinika FN U sv. Anny a LF MU Brno ²
Published in: Kardiol Rev Int Med 2011, 13(4): 254-257
Category: Specialist News

Overview

Ticagrelor is an oral, reversible, direct P2Y12 adenosine diphosphate (ADP) receptor antagonist with faster onset of action and more pronounced antiplatelet activity than clopidrogel. It was tested in a large multicentric PLATO study (180 mg loading dose, 90 mg twice daily maintenance dose) against clopidrogel (300–600 mg loading dose, 75 mg maintenance dose) in 18,624 patients with acute coronary syndrome with or without ST elevations. After 12 months, composite of cardiovascular death, heart attack and stroke occurred in 9.8% patients treated with ticagrelorem compared to 11.7% of patients on clopidrogel (p < 0.001). Heart attack alone occurred in 5.8% of patients on ticagrelor compared to 6.9% of patients on clopidrogel (p = 0.005), cardiovascular death occurred in 4.0% vs. 5.1% (p = 0.001) and stroke in 1.5% vs. 1.3% (p = 0.22). No difference was observed in the incidence of large bleeding (11.6% vs. 11.2%, p = 0.43).

Keywords:
ticagrelor – PLATO – antiaggregation – myocardial infarction

Sources

1. Walentin L, Becker RC, Budaj A et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndroms. N Engl J Med 2009; 361: 1045–1057.

2. Bultas J. Tikagrelor. Remedia 2011; 21: 116–125.

3. Špinar J, Vítovec J. Komu zvoní hrana. Kardiol Rev 2009; 11: 197–199.

4. Storey RF, Becker RC, Harrington RA et al. Characterization of dyspone in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011; v tisku.

5. Storey RF, Becker RC, Harrington RA et al. Pulmonary function im patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and PatientsOutcomes Pulmonary Function Substudy). Am J Cardiol 2011; 108: 1542–1546.

6. U.S. Food and Drug Administration. Brilinta^TM Prescribing Information. http://www.accessdata.fda.gov/drugsatfda/label/2011/022433s000lbl.pdf.

Labels

Paediatric cardiology Internal medicine Cardiac surgery Cardiology

Non-sarcomeric hypertrophic cardiomyopathies in adults

Peripartum cardiomyopathy

Tachycardia-induced cardiomyopathy

There’s no hypertrophy like hypertrophy, or don’t forget amyloidosis

Pericardial calcification

Atherosclerosis of the intracranial arteries – current view, 1st part.

Non-invasive pulse wave analysis in patients with acute decompensation of chronic systolic heart failure.

Young woman with syncopes

Rare cause of mechanical aortic valve dysfunction

Article was published in

Cardiology Review

2011 Issue 4